PEspeaks

Feb 01, 2012
Pharmaceutical Executive
Personalized medicine, which targets individualized treatment and care based on personal and genetic variations, holds much promise for the pharmaceutical industry.
Feb 01, 2012
Pharmaceutical Executive
William Looney looks at the three P’s of effectiveness research: PCORI, Priorities, and Politics
Jan 30, 2012
Pharmaceutical Executive
New pharma supply chains, where chill control and traceability challenges will be far more critical, will emerge over the next decade, So it’s time, argues Julian Mosquera, for the industry to upgrade its capabilities.
Jan 18, 2012
From Pharmaceutical Technology
Forget illegal immigrants, it is machines that are stealing American jobs. For some medical practice areas, however, digital details haven’t sufficiently stepped in where their human sales rep predecessors have stepped (or have been pushed) out, according to a survey of U.S. physicians.
Jan 18, 2012
Pharmaceutical Executive
By admin
The 2011 Edelman Health Barometer suggests that—in the same way that we spread colds, diseases, and other illnesses from person to person—good health and healthy behaviors can also be spread. Can pharma play a pivotal role in the good-health epidemic?
Jan 18, 2012
Pharmaceutical Executive
Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.
Jan 12, 2012
Pharmaceutical Executive
One of the few positive notes struck in this week’s 30th Annual J.P. Morgan Healthcare Conference (held in San Francisco) was the announcement by Kevin Willsey, J.P. Morgan’s co-head of investment banking for North America, that the U.S. economy would grow 2.5 percent in 2012
Jan 11, 2012
Pharmaceutical Executive
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price?
Jan 10, 2012
Pharmaceutical Executive
Outgoing CEO Michael McCallister said one of Humana’s primary strategies going forward is to keep patients out of hospitals and other healthcare institutions, when possible.
Jan 09, 2012
Pharmaceutical Executive
In 2011, the patient’s clout as a stakeholder was firmly established, as reflected in several industry conferences. What’s next for the patient in 2012?
native1_300x100
lorem ipsum